CFC-propelled inhalers no longer available by Dec.

CFC-propelled inhalers no longer available by Dec. 31 2008 The U.S . Meals and Medication Administration today released a public health advisory to alert individuals, caregivers and healthcare professionals to switch to hydrofluoroalkane -propelled albuterol inhalers because chlorofluorocarbon -propelled inhalers will never be available in america after Dec. 31, 2008. CFC-propelled albuterol inhalers are being eliminated because they are harmful to the environment by contributing to depletion of the ozone level above the Earth’s surface area. Three HFA-propelled albuterol inhalers have already been authorized by the FDA: Proair HFA Inhalation Aerosol, Proventil HFA Inhalation Aerosol, and Ventolin HFA Inhalation Aerosol.

The research consortium and new individual registry are significant developments for the EGID community and provide patients the unprecedented opportunity to participate in the research procedure, according to Rothenberg. Individuals also will be able to provide targeted insight and have increased presence to ongoing work.. The registry is located at: Its purpose is to make a single, international database with information submitted by patients with EGID and their own families. Establishing such a database will enable CEGIR investigators to identify and recruit patients with EGID for new research studies directed towards improving treatments and clinical care. For enrolled individuals and caregivers, the registry offers the opportunity to receive direct notification of research studies for which they might be eligible, periodic research updates, patient advocacy info, and the ability to contribute to EGID study/investigator training.